1Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany.
Lupus. 2013 Dec;22(14):1523-5. doi: 10.1177/0961203313504145. Epub 2013 Sep 6.
We report the case of a 19-year-old woman with progressive proliferative lupus nephritis (LN) class III after induction and maintenance therapy with mycophenolate mofetil (MMF). Despite a satisfying clinical improvement proteinuria progressed under this medication. We treated the patient with additional belimumab after discussing other options. Following treatment with belimumab, proteinuria rapidly improved to almost normal levels and clinical remission lasted. Belimumab might hold promise for this indication.
我们报告了一例 19 岁女性患者，在接受霉酚酸酯（MMF）诱导和维持治疗后出现进行性增殖性狼疮肾炎（LN）III 级。尽管该药物治疗后临床改善令人满意，但蛋白尿仍在进展。在讨论了其他选择后，我们用贝利尤单抗治疗了该患者。使用贝利尤单抗治疗后，蛋白尿迅速改善至接近正常水平，且临床缓解持续。贝利尤单抗可能对这一适应证有前景。
